^
    Back
    Association details:
    Biomarker:PD-L1 expression
    Cancer:Triple Negative Breast Cancer
    Drug:Cosela (trilaciclib) (CDK4 inhibitor, CDK6 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)

    Excerpt:
    ......
    Trial ID:
    PRESERVE 2
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Clin Cancer Res
    Title:

    Trilaciclib prior to chemotherapy in patients with metastatic triple-negative breast cancer: final efficacy and subgroup analysis from a randomized phase II study

    Published date:
    12/02/2021
    Excerpt:
    Administering trilaciclib prior to GCb prolonged OS irrespective of PD-L1 status but had greater benefit in the PD-L1-positive population….Administering trilaciclib prior to GCb enhanced antitumor efficacy, with significant improvements in OS.
    Secondary therapy:
    carboplatin + gemcitabine
    DOI:
    10.1158/1078-0432.CCR-21-2272
    Trial ID:
    NCT02978716
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    SITC 2021
    Title:

    339 Immune profiling to investigate improved survival in patients with metastatic triple-negative breast cancer receiving trilaciclib prior to chemotherapy

    Published date:
    11/09/2021
    Excerpt:
    Of 68 patients who received trilaciclib prior to GCb, tumor response status and RNA sequencing data were available for 51 patients, comprising 24 responders and 27 non-responders. Among patients with PD-L1–positive tumors, responders had a greater peripheral immune response at baseline compared with non-responders…
    DOI:
    http://dx.doi.org/10.1136/jitc-2021-SITC2021.339
    Trial ID:
    NCT02978716